A Schedule III drug is a controlled substance that has an accepted medical use and a moderate to low potential for physical and psychological dependence. It sits in the middle of the five-tier classification system created by the Controlled Substances Act, meaning it’s considered less dangerous than Schedule I or II drugs but still regulated because of its potential for misuse. Common examples include ketamine, anabolic steroids, testosterone, and combination products containing limited amounts of codeine.
How the Scheduling System Works
The U.S. federal government classifies all regulated drugs into five schedules based on three factors: how likely the drug is to be abused, whether it has an accepted medical use, and how much physical or psychological dependence it can cause. Schedule I is the most restrictive category (drugs like heroin and, currently, marijuana), while Schedule V is the least restrictive (certain cough preparations and similar low-risk medications).
Schedule III falls in the middle. To land here, a drug must have a currently accepted medical use, a lower potential for abuse than Schedule I or II substances, and the capacity to cause moderate to low dependence. That’s a meaningful distinction from Schedule II, which includes drugs like oxycodone and fentanyl that carry a high potential for severe dependence.
Common Schedule III Drugs
The drugs in this category span several medical fields. Anabolic steroids, including testosterone, are Schedule III because they’re medically necessary for hormone therapy but frequently misused for performance enhancement. Ketamine, widely used as an anesthetic and increasingly prescribed for treatment-resistant depression, is another well-known example.
Codeine-containing combination products also fall here, but only when the codeine stays below specific concentration limits. Federal law caps these at no more than 90 milligrams of codeine per dosage unit, and the product must contain at least one other active, non-narcotic ingredient in a therapeutic amount. Tylenol with Codeine is the most recognizable example. Pure codeine at higher concentrations is classified as Schedule II.
Prescription Rules for Schedule III
Schedule III drugs are easier to prescribe than Schedule II drugs, which require a new written prescription every time. With Schedule III, your doctor can authorize refills on the same prescription, up to five refills within six months of the original date. After six months, the prescription expires and you’ll need a new one, even if you haven’t used all five refills.
Your doctor can also call in or electronically transmit a Schedule III prescription to a pharmacy, something that isn’t always permitted for Schedule II drugs depending on state law. These more flexible rules reflect the lower risk profile of Schedule III substances.
Federal Penalties for Illegal Possession
Possessing a Schedule III drug without a valid prescription is a federal crime. A first offense carries up to one year in prison and a minimum fine of $1,000. The penalties escalate with prior drug convictions: a second offense means 15 days to two years in prison and a minimum $2,500 fine, while a third or subsequent offense means 90 days to three years and at least $5,000. Courts can also add on the costs of the investigation and prosecution.
State penalties vary widely and can be more or less severe than federal law. Trafficking or distributing Schedule III substances carries significantly harsher consequences than simple possession at both levels.
Marijuana’s Potential Move to Schedule III
One of the biggest ongoing changes to Schedule III involves marijuana. In August 2023, the Department of Health and Human Services recommended that the DEA move marijuana from Schedule I to Schedule III based on a scientific and medical review. The DEA proposed a formal rule to do so in May 2024, drawing over 42,000 public comments.
The process has been slow. A public hearing was scheduled for January 2025 but was postponed due to a legal appeal. Then, in December 2025, President Trump issued an executive order directing the attorney general to expedite the rescheduling process. The order also included provisions related to patient access to full-spectrum CBD products. As of now, marijuana remains Schedule I at the federal level, but the reclassification process is actively moving forward.
If marijuana does become Schedule III, it would not make recreational use legal under federal law. It would, however, open the door for federally recognized medical research, allow cannabis businesses to take standard tax deductions, and signal a significant shift in how the federal government views the drug’s medical potential.
How Schedule III Compares to Other Schedules
- Schedule I: No accepted medical use, high abuse potential. Heroin, LSD, and currently marijuana.
- Schedule II: Accepted medical use but high abuse potential and risk of severe dependence. Oxycodone, fentanyl, Adderall.
- Schedule III: Accepted medical use, moderate to low potential for dependence. Ketamine, testosterone, codeine combinations.
- Schedule IV: Lower abuse potential than III. Benzodiazepines like Xanax and Valium, sleep aids like Ambien.
- Schedule V: Lowest abuse potential among controlled substances. Certain cough preparations with small amounts of codeine.
The practical difference between these categories shows up in how tightly each drug is regulated, from prescription rules and pharmacy storage requirements to the legal consequences of unauthorized possession. Schedule III sits at a middle ground where the drug is recognized as medically useful and relatively manageable, but still carries enough risk to warrant controlled access.